KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested Capital

AbCellera Biologics (ABCL) EBIT Margin (2020 - 2023)

Historic EBIT Margin for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to 719.61%.

  • AbCellera Biologics' EBIT Margin fell 5442700.0% to 719.61% in Q4 2023 from the same period last year, while for Dec 2023 it was 623.8%, marking a year-over-year decrease of 6684000.0%. This contributed to the annual value of 1091.69% for FY2024, which is 4678700.0% down from last year.
  • According to the latest figures from Q4 2023, AbCellera Biologics' EBIT Margin is 719.61%, which was down 5442700.0% from 831.79% recorded in Q3 2023.
  • AbCellera Biologics' EBIT Margin's 5-year high stood at 77.97% during Q1 2021, with a 5-year trough of 831.79% in Q3 2023.
  • For the 4-year period, AbCellera Biologics' EBIT Margin averaged around 192.1%, with its median value being 22.16% (2020).
  • As far as peak fluctuations go, AbCellera Biologics' EBIT Margin skyrocketed by 5473100bps in 2022, and later plummeted by -8690100bps in 2023.
  • Quarter analysis of 4 years shows AbCellera Biologics' EBIT Margin stood at 77.33% in 2020, then dropped by -24bps to 58.53% in 2021, then plummeted by -400bps to 175.34% in 2022, then crashed by -310bps to 719.61% in 2023.
  • Its last three reported values are 719.61% in Q4 2023, 831.79% for Q3 2023, and 511.03% during Q2 2023.